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Background: Non-small cell lung carcinoma (NSCLC) is a complex malignancy that owing to its heterogeneity and
poor prognosis poses many challenges to diagnosis, prognosis and patient treatment. DNA methylation is an
important mechanism of epigenetic regulation involved in normal development and cancer. It is a very stable and
specific modification and therefore in principle a very suitable marker for epigenetic phenotyping of tumors. Here
we present a genome-wide DNA methylation analysis of NSCLC samples and paired lung tissues, where we
combine MethylCap and next generation sequencing (MethylCap-seq) to provide comprehensive DNA methylation
maps of the tumor and paired lung samples. The MethylCap-seq data were validated by bisulfite sequencing and
methyl-specific polymerase chain reaction of selected regions.
Results: Analysis of the MethylCap-seq data revealed a strong positive correlation between replicate experiments
and between paired tumor/lung samples. We identified 57 differentially methylated regions (DMRs) present in all
NSCLC tumors analyzed by MethylCap-seq. While hypomethylated DMRs did not correlate to any particular
functional category of genes, the hypermethylated DMRs were strongly associated with genes encoding
transcriptional regulators. Furthermore, subtelomeric regions and satellite repeats were hypomethylated in the
NSCLC samples. We also identified DMRs that were specific to two of the major subtypes of NSCLC,
adenocarcinomas and squamous cell carcinomas.
Conclusions: Collectively, we provide a resource containing genome-wide DNA methylation maps of NSCLC and
their paired lung tissues, and comprehensive lists of known and novel DMRs and associated genes in NSCLC.
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Non-small cell lung carcinoma (NSCLC) is a common
malignancy characterized by a worldwide high incidence
and low survival rate [1]. NSCLC is a heterogenic disease
which is broadly classified into three major histopatho-
logical subtypes: adenocarcinoma (ADC), squamous cell
carcinoma (SCC) and large cell carcinoma (LCC). This
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distribution, and reproduction in any mediumtreatment, since each subtype presents with a distinctive
prognosis [2] and the choice of therapeutic regimen is
predominantly based on tumor subtype and staging para-
meters [3]. The development of personalized diagnostics
and therapy is leading the way to a new era that may see
us overcome some of the difficulties in treating complex
diseases such as NSCLC.
In the past decade, comparative gene expression profiles
of tumors have been extensively studied [4-6], yielding
useful insights into the molecular hallmarks of carcino-
genesis [7,8]. With the advent of next generation sequen-
cing, genome-wide screening has become an attractive
tool for profiling tumors versus lung tissues [7,9]. DNA
methylation is a very stable epigenetic mark and next gen-
eration sequencing studies have recently shown that manyd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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specific DNA methylation patterns are stabilized during
embryonic development, and faithfully maintained
through cell divisions [12-14]. Nevertheless, established
methylation patterns can be reprogrammed, with tumor
cells undergoing DNA demethylation and de novo methy-
lation through mechanisms not yet completely under-
stood. CDKN2A and RASSF1 are examples of genes found
to be aberrantly methylated in a wide variety of tumors
[15-18], and epigenetic silencing of these genes has also
been reported in NSCLC [19-22]. The great majority of
DNA methylation studies are concentrated on the analysis
of CpG islands located in the promoter areas of pre-
selected genes. However, differentially methylated areas
may be located within genes and at large distances from
the nearest neighboring genes [23,24]. Although data on
methylated genes in NSCLC are rapidly accumulating, un-
biased data concerning specificity of the genome-wide dis-
tribution of methylated loci are still scarce.
In this study, we used Methyl-DNA Capture (Methyl-
Cap) and high-throughput sequencing (MethylCap-seq,
[25]) to perform a genome-wide DNA methylation
screening of NSCLC tumors and paired adjacent lung
tissues. With this approach, we sought to identify
genome-wide aberrant methylation patterns of NSCLC.
Specific differentially methylated regions would be
promising candidate molecular markers for non-invasive
diagnostics using circulating tumor DNA, and increase
the number of possible targets for epigenetic therapy.Results
Methylation profiles in NSCLC-study outline
We performed genome-wide DNA methylation analysis of
NSCLC using the MethylCap assay followed by high-
throughput sequencing: MethylCap-seq (Figure 1A). We
used DNA isolated from seven NSCLC tumors and paired
lung tissues. Data regarding the samples used in this study
can be found in Table 1 and Additional file 1. As controls,
we prepared fully methylated and fully unmethylated gen-
omic DNA. The DNA samples were sheared and then
enriched for methylated DNA using the MethylCap pro-
cedure [25]. This is based on the capture of methylated
DNA by biotinylated methyl-binding domain protein
(MBD), which is then retrieved by binding to
streptavidin-coated beads (Figure 1B). The recovered
DNA was directly sequenced using the Illumina Genome
Analyzer IIx next generation sequencing platform. For
each DNA sample, we performed two independent en-
richment procedures and sequence runs. Total numbers
of sequence reads, mapped reads and unique reads for
each sample are represented in Additional file 2. For th
identification of differentially methylated regions (DMRs)
we employed a rigorous normalization procedure and avariety of bioinformatics tools (Figure 1C). We used
MethylCap-seq data obtained from artificially prepared
fully unmethylated and fully methylated DNA samples
for normalization of the data and assignment of DMRs.
The bioinformatics approach is described in detail in
Additional file 3 and Additional file 4. Relative methyla-
tion scores were used to build an individual methylation
profile for each sample. Subsequently, we compared the
profiles to identify highly significant DMRs between
tumors and paired lung tissues, and between the sub-
types of tumors. Finally, we validated the MethylCap-seq
results by bisulfite sequencing and methyl-specific PCR
of selected DMRs.Global analysis of genome-wide methylation patterns of
NSCLC
To assess the reproducibility of the MethylCap-seq pro-
cedure, we first performed a self/self comparison of the
replicate experiments. This yielded an average Pearson’s
correlation coefficient of 0.89 (Figure 2A and Additional
file 5), indicating excellent reproducibility between inde-
pendent experiments. Next, we compared methylation
signal in tumors with matched healthy lung tissues; the
average correlation coefficient between the two was
0.83, indicating a generally high similarity in the methy-
lation patterns of the matched tumor and lung samples
(Figure 2B and Additional file 6). Collectively, these
analyses establish the high reproducibility and specificity
of the MethylCap-seq procedure that we used. To allow
visual inspection of the methylation signal and DMRs,
raw reads and log P-values of differential methylation
were uploaded in the University of California, Santa Cruz
(UCSC) Genome browser, where DMRs can be visually
inspected (Figure 2C). To focus on the most significant
DMRs, we used a very stringent P-value threshold of
10-18, corresponding to a false discovery rate ≤ 10-15
(Additional file 7). Non-repetitive regions with P-value
≤10-18 were projected onto the genome and visua-
lized as genome-wide maps of differential methylation
(Figure 2D and Additional file 8). This revealed that in
the non-repetitive fraction of the genome, tumors dis-
played higher overall hypermethylation than the match-
ing lung tissues. This is consistent with the notion that
de novo methylation and hypermethylation of promoter
CpG islands are associated with carcinogenesis [27].
The DMRs were analyzed according to general hall-
marks of their genomic localization (Figure 2E). Com-
pared with the general distribution of randomly sampled
regions across the genome (label “Random regions”), we
found that promoter areas were particularly enriched
among the DMRs, both hypo- (P=5.7 × 10-3) and hyper-
methylated (p=5.3 × 10-4). Although we removed most
signals from repetitive regions by keeping only uniquely
Figure 1 Experimental design for profiling of DNA methylation patterns in non-small cell lung carcinoma. (A) Overall view of the steps
followed to generate the profiles (ADC: adenocarcinoma; LCC: large cell carcinoma; MBD: methyl-binding domain protein; N: Lung; SCC:
squamous cell carcinoma; T: tumor), (B) MethylCap using methyl-binding domain proteins: Sheared genomic DNA is used as input fraction
(methyl groups in red) and incubated with beads [26], coated with streptavidin (green)-biotin (yellow)) and linked to methyl-binding domain
protein (blue) to capture methylated DNA. Captured fragments are subjected to high-throughput sequencing. (C) Summary of the bioinformatics
approach used to generate the methylation profiles.
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reads and flanking regions were still above background
and allowed us to test for differential methylation. This
revealed that some specific repeat classes such as LINE
and satellites were also differentially represented in theTable 1 Data from patients used for MethylCap-seq and bisul
Sample ID Tissue type Patient ID Stage Overall survival (m
2213 N healthy SCC1 IIB 2,43
2214 T SCC
2235 N healthy SCC2 IIB 51,23
2236 T SCC
2245 N healthy ADC1 IB 12,57
2246 T ADC
2255 N healthy ADC2 IA 98,93
2256 T ADC
2257 N healthy ADC3 N/A N/A
2258 T ADC
2261 N healthy SCC3 IIB 6,77
2262 T SCC
22he healthy LCC1 IB 35,73
22tu LCC
ADC: adenocarcinoma; LCC: large cell carcinoma; N/A: not applicable; SCC: SquamoDMRs, with satellite repeats being particularly hypo-
methylated in tumors when compared with lung tissues
(P=1.3 × 10-5). By contrast, LINE repeats are relatively
underrepresented in the DMRs (hypo and hypermethyla-
tion), indicating that the methylation status of the bulkfite sequencing validation
onth) Survival status Gender Age at diagnosis Ethnicity
Alive M 54,54 Caucasian
Deceased M 73,73 Caucasian
Alive F 66,26 Caucasian
Deceased F 54,26 Caucasian
N/A M 78,96 Caucasian
Alive M 70,03 Caucasian
Deceased F 56,58 Caucasian
us cell carcinoma.
Figure 2 Global analysis of DNA methylation patterns in non-small cell carcinoma. (A) Correlation between experimental replicates. Each
point represents the raw methylation signal (mean coverage in 10 bp bins). Density of points (log10 scale) is shown in different shades of blue.
Pearson’s correlation coefficient is denoted in the top left corner of each scatter plot. (B) Correlation between tumor (x axis) and paired lung
tissue sample (y axis). (C) Raw reads from a lung sample (above panel) and its matching tumor sample (middle panel) in the position
chr2:176,716,200 to 176,738,910 viewed in the UCSC genome browser; normalized P-value is depicted in the bottom panel. Y-axis depicts the
number of sequence reads in each region per sample. Dashed line represents the maximum number of reads (highest peak) in each sample; (D)
Representation of the distribution of hypomethylated (green) and hypermethylated (red) regions across chromosomes in a tumor versus paired
lung sample. (E) Composition of hypo- and hypermethylated regions in comparison to randomly sampled regions across the genome. Bars
indicate the mean proportions of regions covered by each distinct genomic feature. Error bars denote standard error of the mean. Promoters
were defined as regions ± 1 kb from all Ensembl transcription start site. Distinct classes of repeats were retrieved from the UCSC Table Browser
(RepeatMasker table for hg18). Repeats were excluded from all subsequent features. Random regions were sampled across the genome
independently seven times and each time their number was matched to the number of differentially methylated region in one sample pair.
Statistical testing was done against random regions using one-tailed Student’s t-test (*P-≤0.01; **P-≤0.001; ***p≤0.0001).
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and paired lung counterparts.
Differentially methylated regions in NSCLC
We observed a total of 14,742 DMRs in the seven
NSCLC tumor samples (Additional file 9), that is regions
found to be differentially methylated in at least one
tumor when compared with its lung counterpart with a
two-fold change difference in methylation signal. Per-
forming unsupervised cluster analysis with these DMRs
revealed that the samples clustered according to the
histological subtype of the tumors (Figure 3). In particu-
lar, hypermethylated DMRs were overrepresented in
SCC samples. The dendogram of the DMRs indicated
the presence of nine major subgroups of DMRs. Two of
these were composed of generally hypermethylated (red)
or hypomethylated (green) DMRs. These were plotted
on the chromosomes, revealing that the ‘red’ DMRs
were scattered throughout the chromosomes. By con-
trast, the ‘green’ DMRs displayed a more localized distri-
bution towards the chromosome ends (Figure 3B),
showing on average 3.5-times greater enrichment than
random regions (P=6.8 × 10-6). Subtelomeric hypomethy-
lation has been found to be associated with risk of devel-
oping cancer [28].
We found 57 DMRs present in all tumor samples, of
which 50 were hypermethylated and 7 were hypomethy-
lated. An example of two DMRs in all samples, including
the replicate experiment can be found in Additional file
10. We also analyzed DMRs in relation to NSCLC sub-
types. We found 287 DMRs unique for SCC and 26
DMRs unique for ADC (Additioonal File 11). These
DMRs were classified by hyper- and hypomethylation
and their genomic locations relative to genes (Figure 3B).
We found that the ADC-specific DMRs had a genomic
distribution similar to that observed for the DMRs
present in all seven tumors, while for SCCs, DMRs within
genes were concentrated in the gene body. SCC also pre-
sented considerably more subgroup-specific DMRs than
ADC and ‘All-sample’; this could be explained by the no-
tion that SCC is a relatively homogeneous tumor type.
For the DMRs that fall in gene areas, we analyzed
which types of genes were present in each of the three
groups (Figure 3C and Additional file 11). We found that
for the DMRs present in all tumor samples, more than
75% of the associated genes belonged to the class of tran-
scriptional regulators. For SCC-specific DMRs, we
observed a considerable heterogeneity in the functional
categories of associated genes. Nevertheless, there was an
overrepresentation of genes involved in transcriptional
regulation, organization of the cytoskeleton and cell cycle
regulation. We note that while some of the DMRs were
associated with genes that had been previously reported
to be differentially methylated in lung tumors, such asAPC, CDH13, CDKN2A, DAPK, hMLH1, HOX genes,
OTX1, HOX2 and many others [22,29-32], we also found
DMRs which, to the best of our knowledge, have not
been previously reported to be associated with methyla-
tion in NSCLC or other types of cancer.
Validation of differentially methylated regions in NSCLC
by bisulfite sequencing
To validate the results obtained with MethylCap-seq, we
selected five fragments for analysis by bisulfite sequen-
cing. We chose CDKN2A and RASSF1 since hypermethy-
lation of these genes has been widely reported in a variety
of cancers including NSCLC [15,21,22], and the EN1 pro-
moter region since hypermethylation of EN1 had been
previously reported in a lung tumor cell line [29] but not
yet in primary NSCLC tumors. Since we observed that
the region upstream of EN1 was highly hypermethylated
in the tumors and involved a region of more than 15 kbp
(Figure 4A), we selected two extra fragments within this
region, in addition to the EN1 promoter. The other two
fragments were located at positions chr2:119,331,343 to
119,331,692 and chr2:119,328,097 to 119,328,400 and we
named them Frag_01 and Frag_02, respectively. Selection
of the fragments for bisulfite sequencing analysis was
based on the MethylCap-seq data (Figure 4).
To assure sufficient depth of coverage for quantitative
analysis, we sequenced 36 individual clones from each
fragment and each bisulfite-converted DNA sample.
Figure 4B shows an example of the methylation status
for one fragment of a paired sample. The methylation
status of the five fragments in all seven paired NSCLC/
lung tissue samples is summarized in Figure 4C; full
data for all samples is available in Additional files 12
and 13. We also examined potential differences in
methylation according to tumor histology. To perform
this analysis we grouped the samples in four categories:
all clones from the lung tissues of patients (ADC_N and
SCC_N) and clones from tumors (ADC_T and SCC_T),
(Figure 4D and Additional file 14). We observed a sta-
tistically significant difference (P≤0.0001), not only be-
tween tumors and lung tissues, but also between ADC
and SCC for all fragments analyzed by bisulfite sequen-
cing. This identifies these fragments as candidate mar-
kers for differentiating tumors versus paired lung tissues,
and also between tumor subtypes. Moreover this finding
validates the MethylCap-seq data, since the methylation
status determined by bisulfite sequencing correlated
quantitatively with the MethylCap-seq data (Figure 4E).
Screening by methylation-specific PCR verifies
methylation differences between tumor and paired lung
tissues, and between tumor subtypes
To screen the methylation status of selected DMRs in a
larger sample set we used methylation-specific PCR
Figure 3 (See legend on next page.)
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Figure 3 Differentially methylated region in non-small cell carcinoma versus paired lung tissue samples. (A) Heatmap of 14,742 most
significant DMRs, picturing regions with mostly hypermethylated (top), mostly hypomethylated (middle), and mixes (bottom). Color bar at the
bottom represents the log ratio of the normalized signal in tumor versus. lung (red= hypermethylation, green= hypomethylation). Dashed line
represents cut in the dendogram, generating nine groups of DMRs. The DMRs from the two most distinctive groups are depicted on the
chromosomes. Red: cluster containing regions hypermethylated in all samples; green: cluster containing regions hypomethylated in all samples.
(B) Bar plot showing mean enrichment of DMRs at chromosome ends calculated as ratio between proportion of 1 Mbp region at chromosome
ends and total proportion of each chromosome covered by DMRs. Error bars show standard error of mean of all chromosomes. Statistical testing
was done against random regions using one-tailed Student’s t-test (***P≤0.0001). (C) DMRs distribution relative to gene position. Number of
hyper- and hypomethylated genes and regions (outside gene area), and their distribution as in promoter, gene body and 3′ UTR (top panel: all
seven samples; middle panel: squamous cell carcinomas, bottom panel: adenocarcinoma). (D): Gene function distribution of the differentially
methylated genes showing number of hyper- and hypomethylated genes relative to gene classes or function. DMR: differentially methylated
regions; UTR: untranslated region.
Hughes Carvalho et al. Epigenetics & Chromatin 2012, 5:9 Page 7 of 18
http://www.epigeneticsandchromatin.com/content/5/1/9(MSP) [33]. Here, we selected RASSF1, CDKN2A,
Frag_01 and Frag_02 because they were the most signifi-
cant differentially methylated fragments in the bisulphite
sequencing experiments. We added ZIC4 because it was
one of the DMRs not yet reported as methylated in
NSCLC and presented a high difference in relative
methylation score between lung and tumor samples. We
screened 96 samples (48 NSCLC and paired lung sam-
ples), and used totally methylated and totally unmethy-
lated DNA samples as controls for the specificity of the
MSP assays. Results for the seven paired samples used in
MethylCap-seq are displayed in Figure 5. Data for all
96 samples are summarized in Table 2 and shown in
Additional file 15.
MSP is a more qualitative approach than bisulfite se-
quencing. In MSP, selective amplification depends on
the methylation status of only the CpGs present in the
designed primers, which were two or three CpGs de-
pending on the fragment. For each methylated (M) pri-
mer set, amplification of the fragment is dependent on
methylation of the CpGs that are present in the se-
quence targeted by the “M” primer; while each unmethy-
lated (U) primer set requires unmethylated CpGs in the
referred sequence for amplification. In the 48 paired
samples analyzed, CDKN2A showed frequent amplifica-
tion with the M primer set in lung samples (24 out of
48), although the amplified bands were often of low in-
tensity. Tumors had a much larger number displaying
amplification with both M and U primer sets. Of the 47
tumors, 36 displayed amplification with the M primer
set, and two of the tumors displayed amplification only
with the M primer set. For RASSF1 and ZIC4, 41 paired
samples were available. Both fragments differentiated be-
tween lung and tumor samples, whereas no methylation
was detected in lung samples. ZIC4 showed methylation
in more than 70% of the tumors, which is much higher
than the 41% found for RASSF1. The findings for
RASSF1 are in accordance with other studies [18]. Also,
Frag_01 presented no amplification with the M primer
set in the lung samples, in the Frag_02 M primer set
only 5 out of 48 were amplified. In tumors, we observedfragment amplification in 29out of 48 samples for
Frag_01 and 36out of 48 samples for Frag_02 with the M
primer sets. Differences in methylation status were sig-
nificant in tumors versus lung samples for all 5 frag-
ments, with a p-value< 0.02 for CDKN2A and
P< 0.0001 for the other four fragments (Figure 5B).
Frag_01, Frag_02 and ZIC4 present a much lower P-
value, indicating they may be better tumor markers than
CDKN2A and RASSF1. We also observed that significant
differences between SCC and ADC were only found for
Frag_01 (Figure 5C). In conclusion, the MSP results val-
idate the MethylCap-seq data, since the results obtained
for all five fragments were consistent with the significant
DMRs in all tumors, and Frag_01 appeared as part of the
SCC-specific DMRs in the MethylCap-seq data.
Discussion
To date, genome-wide methylation studies in NSCLC
have concentrated on specific areas of the genome [30],
promoter regions [34-36] or sets of pre-selected candi-
date genes [19,37]. Recently Kwon et al. [38] published a
report on genome-wide analysis of DNA methylation in
NSCLC. However, they also concentrate the analysis on
a selection of candidate genes. In our study, we per-
formed an unbiased genome-wide DNA methylation
analysis of seven individual patients with NSCLC and
their adjacent lung tissues. We combined MethylCap
with high-throughput sequencing (MethylCap-seq) to
draw detailed methylome maps of NSCLC tumors and
paired lung tissues. The replicate experiments showed
that the depth of coverage generated by MethylCap-seq
was sufficient to capture the methylation status of the
entire genome. Moreover, there was a very high degree
of correlation between the replicate experiments, dem-
onstrating the robustness of the MethylCap-seq ap-
proach. As controls for normalization and validation
purposes we made use of fully methylated and fully
unmethylated DNA samples. The MethylCap-seq data of
these controls provide a useful resource for benchmark-
ing of the fully methylated versus fully unmethylated
status of any particular fragment in the genome. Using
Figure 4 Bisulfite sequencing validation for MethylCap-Seq. (A) Sequence reads for the Frag_01 (genomic region located at position Ch2:
119,331,343 to 119,331,692) in a tumor (2214 T) and matching lung tissue (2213 N), plotted in the Genome Browser, showing the distribution of
the 25 CpGs contained in the fragment highlighted in green. Dashed lines represent the highest number of reads in 2213 N and 2214 T. (B)
Methylation status of each CpG in all 36 individually sequenced clones in the same samples and fragment shown in Figure 4A. The middle row
represents the average of methylation in all clones per CpG position. (C) Average of methylation of all clones sequenced per patient in each
fragment (M: control totally methylated DNA; N:lung; T:tumor; U:control totally unmethylated DNA). (D) Average of the methylation status of the
sum of all clones, grouped per histological subtype; comparison betweenadenocarcinoma and squamous cell carcinoma in all fragments were
statistically significant. (E) Correlation between normalized methylation signals from MethylCap-seq and CpG methylation from bisulfite sequence.
Different regions are shown in different colors; lung samples are marked by dots and tumors by stars. Pearson’s correlation coefficient is denoted
above the linear regression curve. *P≤0.001.
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methylation profiles of the seven paired NSCLC/lung
cases which can be viewed in the genome browsers.
This broad view of DNA methylation in NSCLC will
provide new opportunities for the identification ofspecific epigenetic markers of NSCLC that could, for in-
stance, be used for early detection of the disease.
The occurrence of methylated CpGs in the fragments
selected for bisulfite sequencing showed a high quantita-
tive correlation with the reads found by MethylCap-seq
Figure 5 Methylation-specific polymerase chain reaction screening in 48 tumors and matching lung tissues. (A) Cropped gel images for
the seven patients used for MethylCap-seq, grouped by histological subtype and controls (M: “methylated primer set”; N: lung; T: tumor; Tot_M:
totally methylated control samples; Tot_U: totally unmethylated control sample; U: unmethylated primer set; ø: blank/water). (B) Histogram of the
methylation status in lung samples and tumor samples in all 48 patients in the five fragments analyzed. (C) Histogram of the methylation status
per histological subtype (statistics were calculated with Fisher’s exact test, two-tailed p-values: *P≤0.02; **P≤0.001 and ***P≤0.01).
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seq data on the fully methylated and fully unmethylated
controls, this demonstrates that MethylCap-seq yields
reliable quantitative information on the methylation sta-
tus of the fragments in a particular DNA sample. This is
important considering that the tumor cell content of
samples to be analyzed will be variable. Provided that
sufficient sequencing depth is achieved, it should be pos-
sible to use MethylCap-seq for the identification of
tumor-specific hypermethylated DNA regions in samples
containing only a minority of tumor cells, and possibly
in circulating tumor DNA isolated from serum samples.
The results obtained with MSP are qualitative in nature,
but this PCR-based approach is very sensitive and may
therefore be used to detect tumor-specific hypermethy-
lated DNA fragments in serum DNA. As a first step in
this direction, we used MSP to investigate the presence
of five DMRs in a larger set of paired samples. The
results confirmed the MethylCap-seq data and demon-
strated that these DMRs are frequently hypermethylated
in NSCLC. In particular, the Frag_01 fragment was
found to be hypermethylated in 13 out of 16 SCC cases
and in none of the ADC, suggesting that this might be a
useful marker for this type of NSCLC, and ZIC4 showed
100% specificity for tumors and higher sensitivity(>70%) than RASSF1. In addition, CDKN2A amplifica-
tion with the M primer was often observed in lung tis-
sue samples, although at much lower amplification levels
when compared with tumor samples. This could reflect
an early event in the methylation status of CDKN2A in
tumorigenesis.
The mapped reads point to differentially methylated
areas across the genome, with some marked preferences
for hypermethylation or hypomethylation in certain gen-
omic regions. There is a strong correlation between CpG
islands and hypermethylation in tumors, with the most
significantly hypermethylated regions associated with
promoter regions of genes. As previously reported by
many groups [40-43], gene promoters are a target of
methylation as an epigenetic regulatory mechanism.
However, our data also reveal a high degree of hyper-
methylation outside promoter areas at intergenic regions,
and at long distances from genes. This indicates that pat-
terns of DNA methylation may play a role not only by si-
lencing promoters of key tumor suppressor genes, but
also by regulating gene expression in a more complex
manner through distant regulatory elements such as
insulators and enhancers.
We found that satellite regions were particularly hypo-
methylated in the NSCLC tumors when compared with
Table 2 Frequency of methylation by methylation-specific polymerase chain reaction in the 96 samples (48 tumor and matching lung tissue) in five fragments
CDKN2A Frag_01 Frag_02 RASSF1 ZIC4
count
(n)
Sensitivity
(%)
Specificity
(%)
Count
(n)
Sensitivity
(%)
Specificity
(%)
Count
(n)
Sensitivity
(%)
Specificity
(%)
Count
(n)
Sensitivity
(%)
Specificity
(%)
Count
(n)
Sensitivity
(%)
Specificity
(%)
Lung 24/48 75 27 0/47 62 100 9/48 75 56 0/41 42 100 0/39 77 100
Tumor 36/48* 29/47** 36/48** 17/41** 30/39**
Adenocarcinoma13/17 76.5 46.4 5/16 31.3 27.7 12/17 70.6 46.1 8/15 53.3 53.3 7/13 53.9 36.8
Squamous
cell carcinoma
15/16 93.8 53.6 13/16 81.3** 72.2 14/16 87.5 53.9 7/16 43.8 46.7 12/16 75.0 63.2
Sensitivity is calculated using the ratio between methylated (amplified) sample and the total amount of samples analyzed per fragment; specificity is the ratio of the difference between amplification in tumor and in
the matching lung sample (or adenocarcinoma versus squamous cell carcinoma). Statistical significance of the difference between control lung samples and tumors, and between adenocarcinomas and squamous cell
carcionmas were calculated using chi-square. *P<0.02; **P0.0001.
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http://www.epigeneticsandchromatin.com/content/5/1/9lung tissues. Recently, Ting et al. [44] have shown that
overexpression of satellite repeats is associated with dif-
ferent types of cancer. The observed hypomethylation of
these regions in NSCLC would be compatible with their
results. We also found that hypomethylated regions are
often present in subtelomeric regions, in agreement with
the observation that hypomethylation is more frequently
located near chromosome ends in lung cancer [45].
While CpG islands and genes are present in the subtelo-
meric regions of chromosomes, the impact of subtelo-
meric hypomethylation on the regulation of these genes
is currently unclear.
In an alternative approach, we selected the most sig-
nificant DMRs in the individual NSCLC cases (14,742)
and performed unsupervised cluster analysis of the
hyper- and hypomethylated regions in the tumor sam-
ples. We observed that the samples clustered according
to their histological classification. This indicates that
there are DMRs that could not only be used as NSCLC
markers but also as markers for histological classification
of NSCLC tumors. Subsequently we searched for the
specific areas that were differentially methylated in all
tumors when compared with the paired lung tissues, and
specific for the subtypes. We observed that SCCs dis-
played more DMRs than did ADCs did. This observation
could be explained by the heterogeneity of ADCs, which
would result in fewer DMRs shared by all three ADC
samples. The contrary is seen in SCC, which is a more
homogeneous type of NSCLC. This characteristic has
been observed previously in gene expression profiling
studies [4,46].
Remarkably, the majority (>75%) of the hypermethy-
lated genes present in all seven samples encoded for
transcription factors, while the shared hypomethylated
genes were spread among many different functional cat-
egories. Transcription factors play a central role in main-
taining or modifying cell fate, either in normal processes
such as development and cell differentiation, or in can-
cer. Mechanisms of epigenetic regulation via DNA
methylation are not yet completely understood; several
factors such as DNA methyltransferases, chromatin re-
modelling proteins and DNA-binding transcription fac-
tors are involved [47,48]. Therefore, any perturbation
that leads to a decrease in the expression status of those
factors may disrupt important pathways for maintenance
of the differentiated cellular state. Aberrant methylation
can change chromatin structure, rendering DNA binding
sites accessible or inaccessible to transcription factors
leading to activation or silencing of genes important in
cell differentiation and maintenance. It has been recently
shown that hypermethylated genes found in lung tumors
are associated with cellular morphogenetic differenti-
ation [49]. These cellular mechanisms are orchestrated
by transcriptional regulators; therefore changes in themethylation status of their binding sites may disrupt
those processes thus contributing to oncogenesis.
Conclusion
Based on the MethylCap-seq data, we generated a list of
candidate DMRs and associated genes specific for
NSCLC and its subtypes (Table 3). Several of these
DMR-associated genes are known to be hypermethylated
in NSCLC and other types of cancer, strongly supporting
the validity of the data set reported here. For instance,
the observed methylation rates of RASSF1 were in agree-
ment with previously reported results [18]. In the
MetylCap-seq data, hypermethylation of the genomic re-
gion where Frag_01 is located was most significant for
the SCC samples. This was supported by the bisulfite
sequencing and MSP validation experiments, where this
fragment showed significantly more hypermethylation in
SCCs when compared with ADCs or LCCs. In conclu-
sion, this list of candidate DMR markers can be used to
develop sensitive biological markers for NSCLC, which
may enable non-invasive diagnosis and early detection
of the disease, and potentially allow histological classifi-
cation. Collectively, we provide a resource containing
genome-wide DNA methylation maps of NSCLC and
paired lung tissues, and comprehensive lists of DMRs
and associated genes in NSCLC.
Methods
Patient samples
Samples were obtained from the patients with NSCLC
(n = 48) who had undergone surgical lung resection at
Erasmus University Medical Center Rotterdam. Speci-
mens were collected from the tumor and adjacent non-
cancerous lung tissue and studied under an anonymous
tissue protocol approved by the medical ethical commit-
tee of Erasmus University Medical Center Rotterdam.
Tissues were snap-frozen within two hours after surgical
resection in liquid nitrogen pre-cooled isopentane, and
stored at -196 °C or -80 °C until DNA extraction.
Histopathological analysis
Patient samples were independently reviewed by two
pathologists. The cohort included 17 with ADC; 16 with
SCC, seven with LCC , eight unclassified samples, and
paired lung tissues for each tumor sample.
Cell line
The MRC-5 lung fibroblast-like cell line was used as
control. Cells were cultured under standard conditions
using minimum essential medium supplemented with
10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 1% non-essential amino acids and penicillin/
streptomycin. Cells were harvested when they reached
90% confluence.
Table 3 List of most differentially methylated genes in non-small cell carcinoma
Gene Log2 ratio Gene class/type/
biological function
Gene name HGNC ID
Common in all tumors BARX1 4.8 transcription regulator BARX homeobox 1 HGNC:955
PAX9 4.3 transcription regulator paired box 9 HGNC:8623
OTX1 4.0 transcription regulator orthodenticle homeobox 1 HGNC:8521
NPR3 3.8 G-protein
coupled receptor
natriuretic peptide receptor C/guanylate cyclase
C (atrionatriuretic peptide receptor C)
HGNC:7945
FGF12 3.7 growth factor fibroblast growth factor 12 HGNC:3668
ONECUT2 3.6 transcription regulator one cut homeobox 2 HGNC:8139
PRDM14 3.5 transcription regulator PR domain containing 14 HGNC:14001
RAX 3.5 transcription regulator retina and anterior neural fold homeobox HGNC:18662
SHOX2 3.3 transcription regulator short stature homeobox 2 HGNC:10854
DMRTA2 3.1 transcription regulator DMRT-like family A2 HGNC:13908
FER1L4 3.1 unknown fer-1-like 4 (Caenorhabditis.
elegans) pseudogene
HGNC:15801
SIX6 3.1 transcription regulator SIX homeobox 6 HGNC:10892
GATA3 3 transcription regulator GATA binding protein 3 HGNC:4172
SKOR1 3 transcription regulator SKI familytranscriptional corepressor 1 HGNC:21326
HOXA9 3 transcription regulator homeobox A9 HGNC:5109
SALL1 2.9 transcription regulator sal-like 1 (Drosophila) HGNC:10524
IRX2 2.7 transcription regulator iroquois homeobox 2 HGNC:14359
GRIK2 2.7 ion channel glutamate receptor, ionotropic, kainate 2 HGNC:4580
SATB2 2.6 transcription regulator SATB homeobox 2 HGNC:21637
MEIS1 2.5 transcription regulator Meis homeobox 1 HGNC:7000
VAX1 2.4 transcription regulator ventral anterior homeobox 1 HGNC:12660
TBX15 2.3 transcription regulator T-box 15 HGNC:11594
CNTD2 −2.4 unknown cyclin N-terminal domain containing 2 HGNC:25805
ZMYND10 −2.6 unknown zinc finger, MYND-type containing 10 HGNC:19412
MYC −2.9 transcription regulator v-myc myelocytomatosis viral
oncogene homolog (avian)
HGNC:7553
TSPAN9 −2.9 Plasma Membrane tetraspanin 9 HGNC:21640
NAV1 −3.1 unknown neuron navigator 1 HGNC:15989
CPEB3 −3.4 unknown cytoplasmic polyadenylation
element binding protein 3
HGNC:21746
Unique for squamous
cell carcinomas
TRAPPC9 6.5 cell differentiation trafficking protein particle complex 9 HGNC:30832
ABHD2 6.3 hydrolase abhydrolase domain containing 2 HGNC:18717
CTNND1 6.2 transcrption regulator catenin (cadherin-associated protein), delta 1 HGNC:2515
HIST1H2BB 6.2 histone protein histone cluster 1, H2bb HGNC:4751
EMP1 5.8 protein binding epithelial membrane protein 1 HGNC:3333
TBL1XR1 5.6 transcription regulator transducin (beta)-like 1 X-linked receptor 1 HGNC:29529
NXPH1 5.6 protein binding neurexophilin 1 HGNC:20693
ZIC4 5.6 transcription regulator Zic family member 4 HGNC:20393
AOAH 5.4 hydrolase acyloxyacyl hydrolase (neutrophil) HGNC:548
ACTN4 5.4 transporter actinin, alpha 4 HGNC:166
C1orf21 5.2 unknown chromosome 1 open reading frame 21 HGNC:15494
PACSIN2 5.2 transporter protein kinase C and casein
kinase substrate in neurons 2
HGNC:8571
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Table 3 List of most differentially methylated genes in non-small cell carcinoma (Continued)
PMM2 5.2 isomerase phosphomannomutase 2 HGNC:9115
DOT1L 5.1 histone methyltransferase DOT1-like, histone H3 methyltransferase
(Sacchormyces. cerevisiae)
HGNC:24948
WWP2 5 e3 ubiquitin-protein ligase WW domain containing E3 ubiquitin
protein ligase 2
HGNC:16804
GTF3C1 5 transcription regulator generaltranscription factor IIIC, polypeptide 1,
alpha 220 kDa
HGNC:4664
MDN1 5 nuclear chaperone MDN1, midasin homolog (yeast) HGNC:18302
DIDO1 5 transcrption regulator death inducer-obliterator 1 HGNC:2680
HIST1H3C 5 histone protein histone cluster 1, H3c HGNC:4768
ANKRD13B 4.9 unknown ankyrin repeat domain 13B HGNC:26363
CALCB 4.9 hormone calcitonin-related polypeptide beta HGNC:1438
PTPRA 4.9 phosphatase protein tyrosine phosphatase, receptor type, A HGNC:9664
STAT5A 4.8 transcription regulator signal transducer and activator of
transcription 5A
HGNC:11366
LIMK1 4.8 cytoskeleton LIM domain kinase 1 HGNC:6613
SLC23A2 4.7 transporter solute carrier family 23 (nucleobase
transporters), member 2
HGNC:10973
BARX1 4.5 transcription regulator BARX homeobox 1 HGNC:955
NHS 4.5 unknown Nance-Horan syndrome (congenital cataracts
and dental anomalies)
HGNC:7820
MTAP 4.5 glycosyltransferase methylthioadenosine phosphorylase HGNC:7413
FOXK1 4.5 transcription regulator forkhead box K1 HGNC:23480
PCMT1 4.4 O-methyltransferase activity protein-L-isoaspartate (D-aspartate)
O-methyltransferase
HGNC:8728
SETD1A 4.3 transcription regulator SET domain containing 1A HGNC:29010
CENPP 4.2 centromere protein centromere protein P HGNC:32933
KIAA1217 4.1 unknown KIAA1217 HGNC:25428
SLITRK1 4.1 enhances neuronal
dendrite outgrowth
SLIT and NTRK-like family, member 1 HGNC:20297
RORB 4 transcription regulator RAR-related orphan receptor B HGNC:10259
DLGAP1 4 postsynaptic scaffold in
neuronal cells
discs, large (Drosophila)
homolog-associated protein 1
HGNC:2905
C3orf21 4 unknown chromosome 3 open reading
frame 21
HGNC:26639
ST6GALNAC1 4 protein glycosylation ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide
alpha-2,6-sialyltransferase 1
HGNC:23614
ZIC3 3.9 transcription regulator Zic family member 3 (odd-paired
homolog, Drosophila)
HGNC:12874
LYPLA1 3.8 hydrolase lysophospholipase I HGNC:6737
REST 3.8 transcription regulator RE1-silencingtranscription factor HGNC:9966
TMEM132D -2 unknown transmembrane protein 132D HGNC:29411
MAP1LC3B2 -2.1 microtubule microtubule-associated protein 1 light
chain 3 beta 2
HGNC:34390
CBY3 -2.2 unknown chibby homolog 3 (Drosophila) HGNC:33278
RASIP1 -2.3 signal transduction Ras interacting protein 1 HGNC:24716
PRKG1 -2.3 kinase protein kinase, cGMP-dependent,
type I
HGNC:9414
WDR72 -2.4 unknown WD repeat domain 72 HGNC:26790
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Table 3 List of most differentially methylated genes in non-small cell carcinoma (Continued)
KCNQ2 -2.7 ion channel potassium voltage-gated channel,
KQT-like subfamily, member 2
HGNC:6296
BAIAP3 -2.8 G-protein coupled receptor BAI1-associated protein 3 HGNC:948
MAP3K10 -30 kinase mitogen-activated protein kinase
kinase kinase 10
HGNC:6849
Unique for
Adenocarcinomas
MSC 4.4 transcription regulator musculin HGNC:7321
FAM78B 4.1 unknown family with sequence similarity 78,
member B
HGNC:13495
HOXA1 3.6 transcription regulator homeobox A1 HGNC:5099
SEPT9 3.3 enzyme septin 9 HGNC:7323
GAS1 3.3 Cell cycle/growth growth arrest-specific 1 HGNC:4165
PTPRN2 3.1 phosphatase protein tyrosine phosphatase, receptor
type, N polypeptide 2
HGNC:9677
RSPO2 2.7 Wnt receptor
signaling pathway
R-spondin 2 homolog (Xenopus laevis) HGNC:28583
POU3F3 2.6 transcription regulator POU class 3 homeobox 3 HGNC:9216
TRPA1 2.5 transporter transient receptor potential cation
channel, subfamily A, member 1
HGNC:497
SYT6 2.3 transporter synaptotagmin VI HGNC:18638
SLC6A2 2.3 transporter solute carrier family 6
(neurotransmitter transporter, noradrenalin),
member 2
HGNC:11048
LHX1 2.1 transcription regulator LIM homeobox 1 HGNC:6593
RAPGEF5 2.1 small GTPase mediated
signal transduction
Rap guanine nucleotide exchange factor
(GEF) 5
HGNC:16862
GDF10 2.1 growth factor growth differentiation factor 10 HGNC:4215
C3orf45 1.6 unknown chromosome 3 open reading frame 45 HGNC:26781
SLIT2 1.6 differentiation/apoptosis slit homolog 2 (Drosophila) HGNC:11086
ZNF423 −1.6 transcription regulator zinc finger protein 423 HGNC:16762
RHOF −1.8 actin filament organization ras homolog gene family, member F
(in filopodia)
HGNC:15703
Genes were selected based on the average of log2 ratios from the samples in each group. Hypermethylated genes common in all tumors and unique for the ADC
groups were selected based on log2 ratio> 2.5; hypomethylation included all genes from those groups. For SCC we selected the first 50 genes with the highest
log2 ratios in hypermethylation, and log2 ratio<−2.0 for hypomethylated genes. Gene classes and their correspondent biological functions were retrieved from
Gene Ontology (http://www.geneontology.org/) and Protein Knowledgebase UniProtKb (http://www.uniprot.org/).
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Genomic DNA from patient tissues and cultured cells
were extracted by overnight treatment incubation with
lysis buffer and proteinase K, followed by phenol-
chloroform extraction, ethanol precipitation and RNase
digestion.
Artificial demethylation and methylation of genomic DNA
We used DNA extracted from the MRC-5 cell line and
commercially available Universal unmethylated DNA
(UUD; Millipore(Billerica, MA, USA). Fully unmethy-
lated DNA was obtained by whole-genome amplification
using the REPLI-g kit (QiagenQiagen – Germantown,
MD, USA) according to manufacturer protocol, followed
by phenol-chloroform extraction. Fully methylated DNA
was prepared by treating MRC-5 DNA and UUD withM.SssI enzyme (New England Biolabs - Ipswich, MA,
USA) according to the manufacturer’s protocol. In short,
10 μg of DNA was incubated for 2 hours at 37°C with
40 U of M.SssI and 640 μM of S-adenosylmethionine.
DNA was then treated with phenol-chloroform and
recovered by ethanol precipitation.
Methyl-DNA capture
Enrichment of methylated DNA was carried out using
the MethylCap technique. DNA samples were sheared
by sonication to obtain fragments between 200 and
800 bp. Methylated DNA capture was carried out using
an adapted protocol from the MethylMiner Methylated
DNA Enrichment kit (Invitrogen – Carlsbad, CA, USA).
Two adaptations were made. Firstly, 20 μL of beads and
14 μL (7 μg) of MBD-biotin protein were used for 5 μg
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fraction was obtained by resuspending the beads in
200 μL of 1X binding/washing buffer containing 2 μL of
proteinase K (20 mg/ml). The samples were then incu-
bated for 90 minutes at 57 °C with 800 rpm agitation.
Remaining steps were performed following the manufac-
turer’s protocol scaled up to 5 μg of DNA. Before the
samples were used for high-throughput sequencing,
methyl-enrichment was tested by quantitative (q) PCR
(data not shown). qPCR was carried out using SYBR r
green, Phire Hot Start DNA polymerase (Finnzymes -
Vantaa, Finland)), and 1 μL of the enriched samples. Pri-
mer sequences are available in Additional file 16. qPCR
was performed in triplicate and enrichment levels were
calculated as previously described [50].
High-throughput sequencing
High-throughput sequencing (HTS) was carried out on
18 samples: seven tumors (three ADC, three SCC and
one LCC), seven paired lung tissues and four controls
(two artificially fully methylated DNA and two fully
unmethylated DNA). For each sample, DNA recovered
from two independent Methyl Capture experiments was
sequenced. The Illumina Genome Analyzer IIx platform
(San Diego, CA, USA was used for both replicates, one
sample per lane, according to the manufacturer’s proto-
col. In short: after MethylCap, fragments of the methyl-
enriched fraction were end-repaired and ligated to
single-read adaptors. Samples were size-selected to an
average of 320 bp, PCR-amplified and 36 bp sequenced.
The Illumina Casava pipeline was used for base call-
ing, alignment and quality control. Results were mapped
against the reference Human_UCSChg18_AllChromo-
somes using eland_extended by Illumina pipeline 1.6.0.
Bioinformatic analysis
Detailed information about the evaluation and selec-
tion of normalization parameters, and identification,
characterization and selection of DMRs can be found
in Additional file 3.
Bisulfite sequencing
Bisulfite sequencing was carried out on the same 16
samples used for MethylCap HTS. Detailed information
is provided in Additional file 3. In short: bisulfite conver-
sion was carried out using the Epitect kit from Qiagen
following the manufacturer’s protocol. Samples were
amplified using primers specific for the fragments of
interest (Additional file 16). Amplified fragments were
loaded on 2% agarose gels and extracted from the gel
using a NucleoSpin Extract II kit (Machery-Nagel –
Düren, Germany). Fragments were then ligated to
pGEM-t easy vector (Promega - Madison, WI, USA) and
cloned into DH12-β competent cells. Colony PCR wasperformed on 36 colonies and PCR fragments
sequenced. Analysis of methylated and unmethylated
CpGs was executed using two online programs: BISMA
(http://biochem.jacobs-university.de/BDPC/BISMA) and
QUMA (http://quma.cdb.riken.jp).Methylation-specific PCR
To determining the methylation status of the selected
regions, we used MSP [33] in 96 samples (48 tumors and
matching lung tissues). Samples were bisulfite converted
as described for bisulfite sequencing, and amplified using
two different set of primers designed for the methylated
and unmethylated sequences (Additional file 16). The
fully methylated and fully unmethylated DNA samples
were used as controls, and a water blank reaction used as
control for contamination. After amplification, products
were resolved on 2% agarose gels containing ethidium
bromide and visualized under UV transillumination.Statistical analysis
Statistical analysis for bisulfite sequencing was provided
by the BISMA program. In short, Fisher’s exact test was
used for the statistical significance between two bisulfite
sequence groups at each CpG, and a Mann-Whitney U-
test for the statistical significance between two groups of
the entire set of CpG sites. Two-tailed P-value of Fisher’s
exact test was calculated from the 2 × 2 tables at each
CpG site. A Mann-Whitney U-test was used for the stat-
istical significance of the entire set of CpG sites between
the tumor and lung groups. For determination of signifi-
cance in the MSP, we used chi-square distribution. Two-
tailed P-values were determined by the counts of the
amplified bands for each primer in the group of samples
lung/tumor or SCC/ADC. Groups that showed a P-value
< 0.05 were considered significantly different.
Additional files
Additional file 1: TableS1. Data from all samples used in this study.
Additional file 2: TableS2. High-throughput sequencing reads from all
samples and replicate experiments.
Additional file 3: Methods. Detailed description of Bioinformatics
approach and methods [51-55].
Additional file 4: FigureS1. Selection of normalization method.
Distribution of Pearson’s correlation coefficients between replicates for
different normalization methods.
Additional file 5: FigureS2. Correlation between technical replicates.
Scatter plots comparing raw MethylCap-seq signal from two technical
replicates (R1 and R2) for all 14 samples. Each point represents one 10 bp
genomic bin. Density of points (log10 scale) is shown in different shades
of blue. Pearson’s correlation coefficient is denoted in the top left corner
of each scatter plot.
Additional file 6: FigureS3. Correlation between lung and tumor
samples. Scatter plots comparing raw MethylCap-seq signal from healthy
and tumor tissue for six pairs of samples. Each point represents one
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shades of blue. Pearson’s correlation coefficient is denoted in the top left
corner of each scatter plot.
Additional file 7: FigureS4. Selection of P-value threshold. Number of
significant hypo- and hypermethylated regions for different P-value
thresholds. Y-axis shows number of significant regions on log10 scale for
decreasing P-value threshold, shown on the x-axis.
Additional file 8: FigureS5. along each chromosome for each paired
sample. Representation of the log-ratio of relative methylation scores for
tumors vs. paired lung samples for each sample pair showing DMRs
along each chromosome. Green colors marks hypomethylation in tumor,
negative log-ratio≤2, and red colors marks hypermethylation in tumor,
positive log-ration>2.
Additional file 9: TableS3. Table with all DMRs found in this study.
14472 DMRs with chromosomal coordinates, log2 ratio, position where
DMR is located regarding to genes and gene identities for DMRs that are
in gene areas.
Additional file 10: FigureS6. MethlCap-seq reads of two DMRs in all
seven samples and replicate experiments. All 14 samples and two
replicate experiments for two DMRs that were present in all tumors. (A)
Sequence reads plotted in the UCSC genome browser spanning 100kbp
in chromosome 2:63,090,001 to 63,190,000; (B) Sequence reads spanning
100 kbp in chromosome 14: 60,000,001 to 60,100,000. Reproducibility can
be observed by the similarity between R1 and R2 of each sample. Red
bar highlight hypermethylated DMRs in each chromosome found to be
present in all seven tumor samples.
Additional file 11: FileS1. Tables with hyper- and hypomethylated
regions separated in “All tumors”, SCC and ADC subtypes. Tables show
hyper- and hypomethylated regions found present in all tumors or that
were either unique for SCC or ADC, separated per tumor subtype and
DMR type.
Additional file 12: FigureS7. Methylation status of CpGs per paired
sample in all five fragments. A) Model of analysis. Blue = unmethylated;
red =methylated. CpGs are horizontally ordered and clones vertically
ordered. Per paired samples in each fragment, the average of
methylation of each CpG is calculated and represented from blue to red
depending on the percentage of clones that were methylated in the
specific CpG. Top panel represents lung samples, bottom panel: tumor
samples. B) All paired analyses for CDKN2A, RASSF1, Frag_01, Frag_02
and EN1.
Additional file 13: FileS2. Tables with bisulfite sequence analysis of
tumor versus lung. Counts and statistics per CpG for all clones in
CDKN2A, RASSF1, Frag_01, Frag_02 and EN1 fragments.
Additional file 14: FileS3. Tables with bisulfite sequencing statistic
analysis of SCC versus ADC. Statistics per CpG for all pooled SCC samples
versus pooled ADC samples.
Additional file 15: FigureS8. MSP screening. Cropped gel images for all
48 samples grouped by histological subtype in the five fragments
analyzed: 17 ADC, 16 SCC, 7 LCC, 8 others (other types and unclassified
NSCLC) M: primer for methylated CpG; N: normal/healthy; T: tumor; *:
samples used in MethylCap-seq; TM: Totally methylated control sample;
TU: Totally unmethylated control sample; ø: blank/water; U: primer for
umethylated CpG.
Additional file 16: TableS4. Primers. Sequence and conditions of
primers used for Bisulfite sequencing and MSP.Abbreviations
ADC: adenocarcinoma; Bp: base pair; DMR: differentially methylated region;
HTS: high-throughput sequencing; LCC: large cell carcinoma; LINE: long
interspersed element; MBD: methyl-binding domain; MSP: methylation-
specific PCR; NSCLC: non-small cell lung carcinoma; PCR: polymerase chain
reaction; SCC: squamous cell carcinoma; UUD: Universal unmethylated DNA;
UTR: untranslated region.
Competing interests
The authors declare no that they have no competing interests.Acknowledgements
We thank Peter Riegman and Monique Oomen for providing patient
samples stored in the Erasmus MC tissue bank, and Ilya Grigorev for the
MRC-5 cell line. We thank Nynke Gillemans for technical assistance and
Thamar van Dijk, Cíntia Bombardieri, Ricardo Leite, Vojka Gouka and Marco
Gouka for helpful discussions during the preparation of this manuscript. We
also thank Alex Pindyurin for this help with the R script. This work was
supported by the Netherlands Genomics Initiative.
Author details
1Department of Cell Biology, ErasmusMC, PO Box 2040, Rotterdam, CA 3000,
The Netherlands. 2Center for Cancer Genomics, ErasmusMC, Rotterdam, The
Netherlands. 3Department of Biology and Computational Biology Unit, Uni
BCCS, University of Bergen, Hoyteknologisenteret, Thormohlensgate 55,
Bergen N-5008, Norway. 4Dutch Consortium for Systems Biology, ErasmusMC,
Rotterdam, The Netherlands. 5Center for Biomics, ErasmusMC, Rotterdam, The
Netherlands. 6Internal Oncology, ErasmusMC, Rotterdam, The Netherlands.
7Department of Bioinformatics, ErasmusMC, Rotterdam, The Netherlands.
8Department of Pulmonology, ErasmusMC, Rotterdam, The Netherlands.
9Center for Biomedical Genetics, ErasmusMC, Rotterdam, The Netherlands.
Authors’ contributions
RHC, VH, BL and SP participated in the concept and writing of the
manuscript. RHC, WvI and CK executed specific experiments. RHC, VH, JH, ST,
TvG, MvV, RB, ER, BL and SP were involved in the analysis of the data. RHC,
VH, JA, BL and SP substantially contributed for interpretation of data. RHC,
AS, JF and SP participated in the design of the experiments. RHC, JA, FG, and
SP participated in editing or revising the manuscript. All authors have read
and approved the final manuscript.
Received: 3 April 2012 Accepted: 22 June 2012
Published: 22 June 2012
References
1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277–300.
2. Little AG: No nodes is good nodes. Ann Thorac Surg 2006, 82:4–5.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung
cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin
Proc 2008, 83:584–594.
4. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van
der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F,
Philipsen S, et al: Gene expression-based classification of non-small cell
lung carcinomas and survival prediction. PLoS One 2010, 5:e10312.
5. Larsen JE, Pavey SJ, Passmore LH, Bowman R, Clarke BE, Hayward NK, Fong
KM: Expression profiling defines a recurrence signature in lung
squamous cell carcinoma. Carcinogenesis 2007, 28:760–766.
6. Liang P, Pardee AB: Analysing differential gene expression in cancer.
Nat Rev Cancer 2003, 3:869–876.
7. Kameyama K, Huang CL, Liu D, Masuya D, Nakashima T, Sumitomo S,
Takami Y, Kinoshita M, Yokomise H: Reduced ING1b gene expression plays
an important role in carcinogenesis of non-small cell lung cancer
patients. Clin Cancer Res 2003, 9:4926–4934.
8. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI: Gene
expression profiling in non-small cell lung cancer: from molecular
mechanisms to clinical application. Clin Cancer Res 2004, 10:3237–3248.
9. Ding L, Mardis ER, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan
MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC,
Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF,
Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K,
Davies S, Guintoli T, Lin L, et al: Genome remodelling in a basal-like breast
cancer metastasis and xenograft. Nature 2010, 464:999–1005.
10. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery
JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V,
Millar AH, Thomson JA, Ren B, Ecker JR: Human DNA methylomes at base
resolution show widespread epigenomic differences. Nature 2009,
462:315–322.
11. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schubeler D:
Chromosome-wide and promoter-specific analyses identify sites of
differential DNA methylation in normal and transformed human cells.
Nat Genet 2005, 37:853–862.
Hughes Carvalho et al. Epigenetics & Chromatin 2012, 5:9 Page 17 of 18
http://www.epigeneticsandchromatin.com/content/5/1/912. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev
2002, 16:6–21.
13. Bird AP, Wolffe AP: Methylation-induced repression–belts, braces, and
chromatin. Cell 1999, 99:451–454.
14. Leonhardt H, Page AW, Weier HU, Bestor TH: A targeting sequence directs
DNA methyltransferase to sites of DNA replication in mammalian nuclei.
Cell 1992, 71:865–873.
15. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J,
Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD,
Maher ER, Latif F: Methylation associated inactivation of RASSF1A from region
3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 20:1509–1518.
16. Kohonen-Corish MR, Sigglekow ND, Susanto J, Chapuis PH, Bokey EL, Dent
OF, Chan C, Lin BP, Seng TJ, Laird PW, Young J, Leggett BA, Jass JR,
Sutherland RL: Promoter methylation of the mutated in colorectal cancer
gene is a frequent early event in colorectal cancer. Oncogene 2007,
26:4435–4441.
17. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR, Rashid A:
Epigenetic alterations in neuroendocrine tumors: methylation of
RAS-association domain family 1, isoform A and p16 genes are
associated with metastasis. Mod Pathol 2005, 18:1632–1640.
18. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R:
Methylation of the RASSF1A gene in human cancers. Biol Chem 2002,
383:907–914.
19. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, Jordan CD, Kiviat NB,
Vesselle H: DNA methylation in tumor and matched normal tissues from
non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2008,
17:645–654.
20. Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK, Lee HC, Wang YC:
Characterization of a multiple epigenetic marker panel for lung cancer
detection and risk assessment in plasma. Cancer 2007, 110:2019–2026.
21. Vaissiere T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, Ferro G,
Paliwal A, Hainaut P, Brennan P, Tost J, Boffetta P, Herceg Z: Quantitative
analysis of DNA methylation profiles in lung cancer identifies aberrant
DNA methylation of specific genes and its association with gender and
cancer risk factors. Cancer Res 2009, 69:243–252.
22. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic
inactivation of a RAS association domain family protein from the lung
tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315–319.
23. Clark SJ: Action at a distance: epigenetic silencing of large chromosomal
regions in carcinogenesis. Hum Mol Genet 2007, 16 Spec No 1:R88–R95.
24. Mayor R, Casadome L, Azuara D, Moreno V, Clark SJ, Capella G, Peinado MA:
Long-range epigenetic silencing at 2q14.2 affects most human
colorectal cancers and may have application as a non-invasive
biomarker of disease. Br J Cancer 2009, 100:1534–1539.
25. Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg HG:
Whole-genome DNA methylation profiling using MethylCap-seq.
Methods 2010, 52:232–236.
26. Teodoridis JM, Hardie C, Brown R: CpG island methylator phenotype
(CIMP) in cancer: causes and implications. Cancer Lett 2008, 268:177–186.
27. Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E, Pikarski E,
Young RA, Niveleau A, Cedar H, Simon I: Evidence for an instructive
mechanism of de novo methylation in cancer cells. Nat Genet 2006,
38:149–153.
28. Rauch TA, Pfeifer GP: DNA methylation profiling using the methylated-
CpG island recovery assay (MIRA). Methods 2010, 52:213–217.
29. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD,
Pfeifer GP: Homeobox gene methylation in lung cancer studied by
genome-wide analysis with a microarray-based methylated CpG island
recovery assay. Proc Natl Acad Sci U S A 2007, 104:5527–5532.
30. Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, Riggs AD, Pfeifer GP:
High-resolution mapping of DNA hypermethylation and hypomethylation in
lung cancer. Proc Natl Acad Sci U S A 2008, 105:252–257.
31. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A,
Flemming N, Seemann S, Distler J, Lewin J, Tetzner R, Weickmann S, Wille U,
Liloglou T, Raji O, Walshaw M, Fleischhacker M, Witt C, Field JK: SHOX2 DNA
methylation is a biomarker for the diagnosis of lung cancer based on
bronchial aspirates. BMC Cancer 2010, 10:600.
32. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD:
Aberrant promoter methylation of multiple genes in non-small cell lung
cancers. Cancer Res 2001, 61:249–255.33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-
specific PCR: a novel PCR assay for methylation status of CpG islands.
Proc Natl Acad Sci U S A 1996, 93:9821–9826.
34. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas
NJ, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS,
Floros J, Fan JB: High-throughput DNA methylation profiling using
universal bead arrays. Genome Res 2006, 16:383–393.
35. Sano A, Kage H, Sugimoto K, Kitagawa H, Aki N, Goto A, Fukayama M,
Nakajima J, Takamoto S, Nagase T, Yatomi Y, Ohishi N, Takai D: A
second-generation profiling system for quantitative methylation analysis
of multiple gene promoters: application to lung cancer. Oncogene 2007,
26:6518–6525.
36. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A,
Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R,
Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD:
A genome-wide screen for promoter methylation in lung cancer
identifies novel methylation markers for multiple malignancies.
PLoS Med 2006, 3:486.
37. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J, Chen L:
Methylation of multiple genes as a candidate biomarker in non-small
cell lung cancer. Cancer Letters 2011, 303:21–28.
38. Kwon YJ, Lee SJ, Koh JS, Kim SH, Lee HW, Kang MC, Bae JB, Kim YJ, Park JH:
Genome-wide analysis of DNA methylation and the gene expression
change in lung cancer. J Thorac Oncol 2012, 7:20–33.
39. Chavez L, Jozefczuk J, Grimm C, Dietrich J, Timmermann B, Lehrach H,
Herwig R, Adjaye J: Computational analysis of genome-wide DNA
methylation during the differentiation of human embryonic stem
cells along the endodermal lineage. Genome Res 2010, 20:1441–1450.
40. Chung JH, Lee HJ, Kim BH, Cho NY, Kang GH: DNA methylation profile
during multistage progression of pulmonary adenocarcinomas. Virchows
Arch 2011, 459:201–211.
41. Esteller M: Epigenetic gene silencing in cancer: the DNA
hypermethylome. Hum Mol Genet 2007, 16 Spec No 1:R50–R59.
42. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK: Aberrant CpG island
hypermethylation profile is associated with atypical and anaplastic
meningiomas. Hum Pathol 2005, 36:416–425.
43. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ,
Nelson HH, Karagas MR, Kelsey KT: Examination of a CpG island
methylator phenotype and implications of methylation profiles in solid
tumors. Cancer Res 2006, 66:10621–10629.
44. Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ,
Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N,
Maheswaran S, Haber DA: Aberrant overexpression of satellite repeats in
pancreatic and other epithelial cancers. Science 2011, 331:593–596.
45. Pfeifer GP, Rauch TA: DNA methylation patterns in lung carcinomas.
Semin Cancer Biol 2009, 19:181–187.
46. Hou J, Lambers M, den Hamer B, den Bakker M, Hoogsteden MC,
Grosveld F, Hegmans J, Aerts J, Philipsen S: Expression profiling-based
subtyping identifies novel non-small cell lung cancer subgroups and
implicates putative resistance to pemetrexed therapy. J Thorac Oncol
2012, 7:105–114.
47. Chatagnon A, Ballestar E, Esteller M, Dante R: A role for methyl-CpG
binding domain protein 2 in the modulation of the estrogen response
of pS2/TFF1 gene. PLoS One 2010, 5:e9665.
48. Clouaire T, de Las Heras JI, Merusi C, Stancheva I: Recruitment of MBD1 to
target genes requires sequence-specific interaction of the MBD domain
with methylated DNA. Nucleic Acids Res 2010, 38:4620–4634.
49. Helman E, Naxerova K, Kohane IS: DNA hypermethylation in lung cancer
is targeted at differentiation-associated genes. Oncogene 2011,
31:1181–1188.
50. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N: Statistical
significance of quantitative PCR. BMC Bioinformatics 2007, 8:131.
51. R Development Core Team: R: A language and environment for statistical
computing. Reference index version: 2.11.1. Vienna, Austria: R Foundation for
Statistical Computing; 2010. http://www.R-project.org. ISBN 3-900051-07-0.
52. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, et al: Bioconductor: open software development
for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
53. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler
D: The human genome browser at UCSC. Genome Res 2002, 12:996–1006.
Hughes Carvalho et al. Epigenetics & Chromatin 2012, 5:9 Page 18 of 18
http://www.epigeneticsandchromatin.com/content/5/1/954. Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Graf S, Johnson N,
Herrero J, Tomazou EM, Thorne NP, Bäckdahl L, Herberth M, Howe KL,
Jackson DK, Miretti MM, Marioni JC, Birney E, Hubbard TJ, Durbin R, Tavaré
S, Beck S: A Bayesian deconvolution strategy for immunoprecipitation-
based DNA methylome analysis. Nat Biotechnol 2008, 26:779–785.
55. Pelizzola M, Koga Y, Urban AE, Krauthammer M, Weissman S, Halaban R,
Molinaro AM: MEDME: an experimental and analytical methodology for
the estimation of DNA methylation levels based on microarray derived
MeDIP-enrichment. Genome Res 2008, 18:1652–1659.
doi:10.1186/1756-8935-5-9
Cite this article as: Hughes Carvalho et al.: Genome-wide DNA
methylation profiling of non-small cell lung carcinomas. Epigenetics &
Chromatin 2012 5:9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
